Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets
Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced today a strategic partnership agreement with two undisclosed...
Deals
Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34%...
Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company...
Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover...
Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
Zhejiang Shimai Pharmaceutical Co., Ltd., a T-cell engager (TCE) specialist founded in 2017, has filed...
Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
Youcare Pharmaceutical Group (SHA: 688658) announced a RMB 1 billion ($147 million) investment to establish...
BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
BrightGene (Suzhou) Bio-Medical Technology Co., Ltd. (SHA: 688166) has filed its prospectus with the Hong...
Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
Bayzed Health Group (HKG: 2609) and Meinian Onehealth Healthcare (Group) Co., Ltd. (SHE: 002044) announced...
Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator
Shandong Ande Healthcare Apparatus Co., Ltd. has released its prospectus and formally applied for listing...
Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial
Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round,...
Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production
Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million...
BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
Bristol-Myers Squibb (BMS) (NYSE: BMY) announced a strategic partnership with the Tigerlily Foundation, a leading...
Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals...
Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs
Eli Lilly and Company (NYSE: LLY) announced a strategic alliance with UNICEF USA this week,...
TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections
TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock...
Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196) announced a strategic licensing agreement with South...
Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading...
Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD...
Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion
Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans...